1. Home
  2. OPRX vs TNXP Comparison

OPRX vs TNXP Comparison

Compare OPRX & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimizeRx Corporation

OPRX

OptimizeRx Corporation

HOLD

Current Price

$12.35

Market Cap

245.7M

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$16.37

Market Cap

201.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPRX
TNXP
Founded
2006
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
245.7M
201.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OPRX
TNXP
Price
$12.35
$16.37
Analyst Decision
Buy
Buy
Analyst Count
6
1
Target Price
$14.83
$70.00
AVG Volume (30 Days)
242.0K
509.0K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$109,506,000.00
$10,299,000.00
Revenue This Year
$19.77
$2.96
Revenue Next Year
$11.33
$750.19
P/E Ratio
$6,842.22
N/A
Revenue Growth
24.18
N/A
52 Week Low
$3.99
$6.76
52 Week High
$22.25
$69.97

Technical Indicators

Market Signals
Indicator
OPRX
TNXP
Relative Strength Index (RSI) 31.29 39.76
Support Level $12.66 $15.93
Resistance Level $13.78 $19.35
Average True Range (ATR) 0.60 1.06
MACD 0.01 -0.21
Stochastic Oscillator 2.97 10.37

Price Performance

Historical Comparison
OPRX
TNXP

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: